tramól-l forðatafla 150 mg
teva b.v.* - tramadolum hýdróklóríð - forðatafla - 150 mg
tramól-l forðatafla 200 mg
teva b.v.* - tramadolum hýdróklóríð - forðatafla - 200 mg
firmagon
ferring pharmaceuticals a/s - degarelix - blöðruhálskirtli - innkirtla meðferð - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
ezetrol tafla 10 mg
n.v. organon* - ezetimibum inn - tafla - 10 mg
fortum stungulyfs-/innrennslisstofn, lausn 2 g
sandoz a/s - ceftazidimum inn - stungulyfs-/innrennslisstofn, lausn - 2 g
fortum stungulyfsstofn, lausn 1 g
sandoz a/s - ceftazidimum inn - stungulyfsstofn, lausn - 1 g
ceftazidima normon (ceftazidime) stungulyfsstofn og leysir, lausn 1 g
laboratorios normon s.a. - ceftazidimum inn - stungulyfsstofn og leysir, lausn - 1 g
ezetimib medical valley tafla 10 mg
medical valley invest ab - ezetimibum inn - tafla - 10 mg
ceftazidima normon (ceftazidime) innrennslisstofn, lausn 2 g
laboratorios normon s.a. - ceftazidimum inn - innrennslisstofn, lausn - 2 g
ezetimib krka tafla 10 mg
krka d.d. novo mesto* - ezetimibe - tafla - 10 mg